Dear Editor, Chi et al.1 have updated the second interim analysis of the MAGNITUDE trial assessing niraparib plus abiraterone acetate with prednisone (AAP) for patients with metastatic castration-resistant prostate cancer (mCRPC). Although niraparib plus AAP as the first-line treatment significantly prolonged radiographic progression-free survival, it showed no benefit on overall survival (OS) of patients with homologous recombination repair gene mutations (HRRm) [hazard ratio (HR): 1.01; 95% confidence interval (CI): 0.75-1.36] and BRCA mutations (BRCAm) (HR: 0.88; 95% CI: 0.58-1.34).